PTPN2 and neoplasm: For instance, by constructing a single-guide RNA (sgRNA) library targeting 2,398 genes and applying genome-wide CRISPR-Cas9 screening in B16 tumor cells, researchers identified protein tyrosine phosphatase non-receptor type 2 as a novel cancer immunotherapy target.